Effects of NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice

Cancer Immunology, Immunotherapy

Volumn 42, Issue 1, 1996, Pages 38-46

  Orucevic, Amila ^a   Lala, P K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Capillary leak syndrome; Interleukin 2 therapy; Mammary adenocarcinoma; NG methyl L arginine; Nitric oxide

Indexed keywords

N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; RECOMBINANT INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CAPILLARY LEAK SYNDROME; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; CAPILLARY PERMEABILITY; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; PLEURAL EFFUSION; PULMONARY EDEMA;

EID: 0030032392     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050249     Document Type: Article

References (58)

1. Albina JE, Abate JA, Henry WL Jr (1991) Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFNγ in the induction of nitric oxide-synthesizing pathway. J Immunol 147: 144
2. Andrade SP, Hart IR, Piper PJ (1992) Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br J Pharmacol 107: 1092
3. Brodt P, Parhar RS, Sanker P, Lala PK (1985) Studies on clonal heterogeneity in two spontaneously metastasizing mammary carcinomas of recent origin. Int J Cancer 35: 265
4. Buttery LDK, Springall DR, Andrade SP, Riveros-Moreno V, Hart I, Piper PJ, Polak JM (1993) Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J Pathol 171: 311
5. Chhatwal VJS, Ngoi SS, Chan STF, Chia YW, Moochhala SM (1994) Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonie mucosa and surrounding peritumoral normal mucosa. Carcinogenesis 15: 2081
6. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55: 727
7. Davison W, Woof C (1978) Comparison of different forms of cadmium as reducing agents for the batch determination of nitrate. Analyst 103: 403
8. Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M (1989) A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J Clin Oncol 7: 477
9. Edwards MJ, Miller FN, Sims DE, Abney DL, Schuschke DA, Corey TS (1992) Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. Cancer Res 52: 3425
10. Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80: 177
11. Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, Echtenacher B, Albini E, Ghezzi P (1994) Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J Immunother 15: 194
12. Fisher RI, Coltman CA, Doroshow JA, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E (1988) A phase II study of interleukin-2 and lymphokine activated killer cells (LAK) in metastatic renal cancer. Ann Intern Med 108: 518
13. G-monomethyl-L-arginine, an inhibitor of nitric oxide production (abstract). Proc Am Assoc Cancer Res 35: 251
14. 15N]nitrate in biological fluids. Anal Biochem 126: 131
15. Hibbs JB Jr, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, Ward JH, Menlove RL, McMurry MP, Kushner JP, Samlowski WE (1992) Evidence for cytokine-inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2-therapy. J Clin Invest 89: 867
16. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada S (1994) Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 70: 847
17. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S (1995) Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 82: 4392
18. Jesmok GJ, Gunther RA (1989) In vivo biology of recombinant interleukin-2 infusion in sheep. Inflammation 13: 267
19. Kahaleh MB, Smith EA, Soma Y, LeRoy EC (1988) Effect of lymphotoxin and tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Clin Immunol Immunopathol 49: 261
20. Kelm M, Feelisch M, Grube R, Motz W, Stauer BE (1992) The biology of nitric oxide: In: Moncada S, Marletta MA, Hibbs JB Jr, Higgs EA (eds) Metabolism of endothelium-derived nitric oxide in human blood. Portland, London, p 319
21. Kennovin GD, Hirst DG, Stratford MRL, Flitney FW (1994) Biology of nitric oxide. Part 4. Enzymology, biochemistry and immunology: In: Moncada S, Feelisch M, Busse R, Higgs EA (eds) Inducible nitric oxide synthase is expressed in tumour-associated vasculature: inhibition retards tumor growth in vivo. Portland, London, p 473
22. G-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87: 3629
23. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 172: 1132
24. G-Methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs. J Appl Physiol 76: 1130
25. G-methyl-L-arginine in cancer patients with shock (abstract). Endothelium 3: s15
26. Klausner JM, Paterson IS, Morel NML, Goldman G, Gray AD, Valeri R, Eberlein TJ, Shepro D, Hechtman HB (1989) Role of thromboxane in interleukin 2-induced lung injury in sheep. Cancer Res 49: 3542
27. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS (1988) Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res 48: 5528
28. Lala PK, Parhar RS (1988) Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ. Cancer Res 48: 1072
29. Lala PK, Parhar RS (1993) Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int J Cancer 54: 677
30. Lala PK, Parhar RS, Singh P (1986) Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol 99: 108
31. Lancaster JR Jr, Hibbs JB Jr (1990) EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc Natl Acad Sci USA 87: 1223
32. Lotze M, Matory Y, Ettinghausen S, Raynor A, Sharrow S, Siepp C, Custer M, Rosenberg SA (1985) In vivo administration of purified human interleukin-2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant interleukin-2. J Immunol 135: 2865
33. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764
34. Mertens WC, Bramwell VHC, Gwadry-Sridhar F, Romano W, Banerjee D, Lala PK (1992) Effect of indomethacin and ranitidine in advanced melanoma patients on high dose interleukin-2. Lancet 340: 397
35. Mertens WC, Bramwell VHC, Banerjee D, Gwadry-Sridhar F, Al-Mutter N, Parhar RS, Lala PK (1993) Chronic oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma. Cancer Biother 8: 229
36. Mier J, Vadrino G, Van der Meer J, Numerof R, Adams S, Cannon J, Bernheim H, Atkins M, Parkinson D, Dinarello C (1988) Induction of circulating tumor necrosis factor as the mechanism for the febrile response to interleukin-2. J Clin Immunol 8: 426
37. Montesano R, Orci L, Vassalli P (1985) Human endothelial cell cultures: Phenotypic modulation by leukocyte interleukins. J Cell Physiol 122: 424
38. Ochoa JB, Curti B, Peitzman AB, Simmons RL, Billiar TR, Hoffman R, Rault R, Longo DL, Urba WJ, Ochoa AC (1992) Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Inst 84: 864
39. G-melhyl-L-arginine and indomethacin on IL-2 induced pulmonary edema and pleural effusion (abstract). Proc Am Assoc Cancer Res 33: 322
40. G-methyl-L-arginine and indomethacin on IL-2 induced capillary leakage in tumor-bearing mice (abstract). Proc Am Assoc Cancer Res 34: 459
41. G-methyl-L-arginine on IL-2 induced anti-tumor killer cell generation in vivo and in vitro (abstract). Proc Am Assoc Cancer Res 35: 521
42. G-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2 induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice. Cell Immunol (in press)
43. G-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates IL-2 induced capillary leak syndrome in healthy mice. J Immunother (in press)
44. G-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2 induced capillary leakage and reduces tumor growth in adenocarcinoma bearing mice. Br J Cancer (in press)
45. Palmer RMJ, Ferrige AS, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524
46. Palmer RMJ, Bridge L, Foxwell NA, Moncada S (1992) The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 105: 11
47. Petros A, Lamb G, Leone A, Moncada S, Bennet D, Vallance P (1994) Effects of nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28: 34
48. Puri RK, Travis WD, Rosenberg SA (1989) Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1α in vivo. Cancer Res 49: 969
49. Rosenberg SA (1989) Clinical immunotherapy studies in the surgery branch of the U. S. National Cancer Institute. Cancer Treat Rev 16 [Suppl A]: 115
50. Rosenberg SA, Mule JJ, Spiess PJ, Reichart CM, Schwarz SL (1985) Regression of established pulmonary metastasis and subcutaneous tumor mediated by systemic administration of high dose recombinant interleukin 2. J Exp Med 161: 1169
51. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Lineham M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson C, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889
52. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735
53. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9: 694
54. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54: 1352
55. Thomsen LL, Miles DW, Happerfiels L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41
56. Welbourn R, Goldman G, Kobzik L, Valeri CR, Hechtman HB, Shepro D (1991) Attenuation of IL-2-induced multisystem organ edema by phaloidin and antamanide. J Appl Physiol 70: 1364
57. Xie K, Huang S, Dong Z, Juang S-h, Gutman M, Xie Q-W, Nathan C, Fidler IJ (1995) Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogated metastasis by K-1735 murine melanoma cells. J Exp Med 181: 1333
58. Zar JH (1974) Biostatistical analysis. Prentice-Hall, Englewood Cliffs, NJ